4.7 Review

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

期刊

出版社

MDPI
DOI: 10.3390/ijms232113332

关键词

CAR-T; manufacturing; toxicities; solid tumor; DRG; cost

向作者/读者索取更多资源

The approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T) has changed the treatment landscape for hematologic malignancies. However, there are still several challenges to be addressed, including the lack of initial responses and early relapse. New strategies are needed to increase the safety profile and shorten the manufacturing process of CAR-T cells therapy. The use of allogeneic CAR-T cells products generated from healthy donors has the potential to overcome these limitations.
The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some hurdles to be tackled. Moreover, new strategies are needed to increase the safety profile or shorten the manufacturing process during CAR-T cells therapy production. Nowadays, most clinically evaluated CAR-T cells products are derived from autologous immune cells. The use of allogeneic CAR-T cells products generated using cells from healthy donors has the potential to change the scenario and overcome many of these limitations. In addition, CAR-T cells carry a high price tag, and there is an urgent need to understand how to pay for these therapies as many of today's current payment systems do not feature the functionality to address the reimbursement gap. Finally, the clinical experience with CAR-T cells for solid tumors has been less encouraging, and development in this setting is desirable.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据